Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other financing activities: 2014-2025

Historic Other financing activities for Coherus Oncology (CHRS) over the last 8 years, with Sep 2025 value amounting to $3,000.

  • Coherus Oncology's Other financing activities fell 70.00% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 60.22%. This contributed to the annual value of $2.5 million for FY2024, which is 29.80% down from last year.
  • Per Coherus Oncology's latest filing, its Other financing activities stood at $3,000 for Q3 2025, which was down 81.25% from $16,000 recorded in Q2 2025.
  • Coherus Oncology's 5-year Other financing activities high stood at $4.6 million for Q4 2022, and its period low was -$2.0 million during Q2 2021.
  • Over the past 3 years, Coherus Oncology's median Other financing activities value was $305,000 (recorded in 2023), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Coherus Oncology's Other financing activities plummeted by 109.11% in 2021, and later surged by 460.98% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Other financing activities stood at $2.2 million in 2021, then spiked by 105.12% to $4.6 million in 2022, then declined by 5.28% to $4.4 million in 2023, then crashed by 44.22% to $2.4 million in 2024, then slumped by 70.00% to $3,000 in 2025.
  • Its Other financing activities stands at $3,000 for Q3 2025, versus $16,000 for Q2 2025 and $264,000 for Q1 2025.